Reactivación del virus de la hepatitis B por ibrutinib

Alventosa Mateu, Carlos; Urquijo Ponce, Juan José; Mena Durán, Armando; Latorre Sánchez, Mercedes; Castelló Miralles, Inmaculada; Linares García, Mariano; Diago, Moisés.
Rev. esp. enferm. dig ; 116(1): 43-43, 2024.
Artículo en Español | IBECS (España) | ID: ibc-229484

Documentos relacionados

  1. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
  2. RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence.
  3. Thrombotic Thrombocytopenic Purpura associated with Pembrolizumab.
  4. Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
  5. Safety and Effectiveness of Vedolizumab in Elderly Patients with Inflammatory Bowel Disease: A Systematic Review & Meta-Analysis.
  6. Clinical and serological resolution of pembrolizumab associated Sjögren's syndrome: long-term follow-up.
  7. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
  8. Generalized hypertrichosis due to secukinumab in a patient with moderate psoriasis: A case of serendipity or zemblanity?
  9. Pembrolizumab-induced agranulocytosis.
  10. Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.